A wellness economist who research health outcomes, he is also an assistant professor of medicine at the Indiana University College of Medicine. Related StoriesNovartis announces FDA acceptance of dual combination bronchodilator Utibron Neohaler for COPD patientsMatricellular proteins could be key therapeutic targets for common ocular disordersLatinos with African ancestry at higher risk for glaucomaGlaucoma may be the second most common reason behind blindness in the usa. Although the system of vision reduction in glaucoma isn’t understood fully, most research has centered on a rise in eye pressure steadily injuring the optic nerve. Most people who develop open-position glaucoma have no symptoms until late in the disease process when substantial peripheral eyesight has been dropped.Food and Medication Administration for spinal fusion treatment of symptomatic degenerative disk disease .2 billion U.S. Marketplace for expandable interbody fusion products. The Luna 360 Program is usually a novel, minimally invasive lumbar interbody fusion gadget for DDD that includes Benvenue Medical's proprietary implant technology. The expandable implant provides backbone surgeons a little delivery cannula for posterior gain access to, and the implant expands to a big footprint. The Luna 360 Implant entails a four-step procedure: deploying through a posterior strategy; expanding in-situ and inside the disc space to revive disc height vertically; filling the implant then, allowing surgeons to put in and maximize the quantity of autologous bone graft post-Luna growth, and lock the implant, securing the 360 level construct.